CD38

Ongoing clinical trials and approved products targeting CD38, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

2ongoing therapy trials
0ongoing imaging trials
0approved products

Target note

Full name
CD38
Nature
Transmembrane glycoprotein with ADP-ribosyl cyclase activity.
Normal expression
Plasma cells, activated lymphocytes, NK cells.
Disease expression
Multiple myeloma, some lymphomas and leukemias.
Value
A target validated by daratumumab; radioligand therapy can reach cells resistant to the naked antibody.
Approaches
Daratumumab labeled with ²²⁵Ac.
Indications explored
Relapsed myeloma, transplant conditioning (phase 1).
Points of caution
Expression on immune cells; data still early.

Ongoing therapy trials · 2Open in the radar →

TrialPhaseStatusSponsorCountries
Actinium Ac 225-DOTA-DaratumumabNCT05363111 · MyelomaPhase 1RecruitingCity of Hope Medical Center1
Actinium Ac 225-DOTA-DaratumumabNCT06287944 · Leukemia / transplant conditioningPhase 1RecruitingCity of Hope Medical Center1

Cite this page

CD38. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/cd38/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.